



21 July 2016
EMA/CHMP/BWP/3354/1999 rev.1
Committee for medicinal products for human use (CHMP)

Guideline on production and quality control of animal immunoglobulins and immunosera for human use

3R's technical update*	January 2016
Agreed by Biologics Working Party	January 2016
Adopted by CHMP	July 2016
Date for coming into effect	September 2016

* This is a technical update to reflect current best practice with regard to implementation of 3Rs approaches and it is not intended as a full revision of this guideline (only sections 1, 3 and 6 are affected). In addition, minor changes have been introduced to reflect the new Agency templates, for example addition of an Executive Summary. All these changes are considered to be minor and uncontroversial and consequently a consultation phase was considered to be unnecessary.

This guideline replaces 'Guideline on production and quality control of animal immunoglobulins and immunosera for human use' (EMA/CPMP/3354/1999).

Keywords	<i>Immunoglobulins, immunosera</i>
-----------------	---



Guideline on production and quality control of animal immunoglobulins and immunosera for human use

Table of contents

Executive summary	3
1. Introduction (background)	3
2. Scope.....	4
3. Legal basis	4
4. Aspects to consider on the production and quality control of animal immunoglobulins and immunosera for human use	4
4.1. Characterisation of the Animal Immunoglobulin/Immuneserum during Development	4
4.2. Points to Consider in Manufacture.....	5
5. The Final Bulk Product.....	9
6. The Finished Product/Release Testing	9
7. Consistency of the Manufacturing Process	10
Annex: Potential Viral Contaminants	11

Executive summary

This guideline provides guidance for the starting material, the manufacturing and quality control of animal immunoglobulins and immunosera for human use.

Specific attention is given to the animals used in production, the antigens for immunisation, the characterisation of the animal immunoglobulins/immunosera during development and the viral safety of these products.

1. Introduction (background)

Animal immunoglobulin or immunosera for human use is prepared from serum or plasma of immunised animals. Purified products consist mainly of immunoglobulin G. Immunosera are at least partially purified products and could thus contain serum components other than immunoglobulins. These medicinal products contain a mixture of different antibodies but are enriched in specific antibodies against a particular target antigen.

The clinical targets of these products are diverse. The preparations in use include anti-lymphocyte/T-cell immunoglobulins/sera, anti-toxins against microbial and other toxins (e.g. *C. botulinum*, digitalis), anti-sera against bacterial and viral agents and anti-sera against the venoms of snakes, scorpions and spiders. In general, the development of immunosera dates back to the beginning of the 20th century when they were the only available treatments for certain life-threatening conditions. In fact, this is still the case for most of these products.

In general, animal immunoglobulins and immunosera are used infrequently and in very few patients. However, the anti-lymphocyte immunoglobulins/sera product group is still important and routinely used in the prophylaxis and treatment of acute rejection episodes in organ transplantations, for the treatment of GvHD in bone marrow transplantations and in the therapy of aplastic anaemia. New developments include immunosera produced from the yolk of immunised hens, for example for the treatment of diarrhoea caused by parasites in AIDS patients. Animal immunoglobulins/immunosera are administered intramuscularly, subcutaneously or intravenously. Some products are diluted in large volumes of physiological solutions before infusion.

The first products consisted of crude sera, which were replaced by purified immunosera as required by the relevant Ph. Eur. monograph. These early products were purified by precipitation, often consisted of complete antibodies and may contain serum components other than immunoglobulins. The manufacturing processes of more recently developed products include more effective purification steps. Products are available with active substances consisting of purified F(ab')₂ or Fab immunoglobulin fragments produced by pepsin or papain digestion of complete immunoglobulin molecules.

Important considerations for the clinical use of animal immunoglobulins/immunosera include the risk of sensitisation of the recipient, the need of preparations with sufficient purity, the viral and TSE safety aspects, adverse effects caused by additives, pyrogens, cell or complement-active aggregates or immune complexes and variability in the specific potency. Therefore, there is a need to use improved manufacturing processes to reduce the amount of heterologous protein, to remove aggregates, to ensure viral safety and to develop appropriate control methods.

The quality of animal immunoglobulins/immunosera should be considered on a case-by-case basis taking into account the individual character of each product, the clinical indication and the availability of alternative products.

Reference is made to the general Ph.Eur monograph Immunoserum ad Usus Humanum, 0084, and to the monographs available for a number of specific immunoserum (Immunoserum botulinum, 0085; Immunoserum diphthericum, 0086; Immunoserum gangraenicum, Cl. novyi, 0087; Cl. perfringens, 0088, Cl. septicum, 0089; Immunoserum gangraenicum, mixtum, 0090; Immunoserum contra venena viperarum europaeorum, 0145, Anti-T-lymphocyte immunoglobulin for human use, animal, 1928).

In accordance with the provisions of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and Directive 2010/63/EU on protection of animals used for scientific purposes, the 3R principles (replacement, reduction and refinement) should be applied to production and control testing of medicinal products.

2. Scope

In this document, the requirements for animal immunoglobulins/immunoserum for therapeutic use in humans are outlined. Animal immunoglobulins/immunoserum to be used for diagnostic purposes in vitro are not the concern of this note for guidance. Those products intended for use in the purification of other products, e.g. by immunoaffinity columns should be shown to be pure and free from adventitious agents by the methods described.

3. Legal basis

This guideline should be read in conjunction with the introduction and general principles and Part I of Annex I of Directive 2001/83/EC, as amended.

Animal immunoglobulins/immunoserum are obtained from sera of different species. Currently, these sera are collected from rabbit, horse, goat and sheep. Other species, like hens, could additionally be used. In general, it is desirable to have alternative products available from sera of different species for use in patients in the event of intolerance against heterologous protein.

Specific and general requirements for the animals used in the manufacturing process are set out under 4.2.1. General reference is made to the relevant Commission Directives. For those species where a TSE risk is known, the requirements specified in the EU Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy via Human and Veterinary Medicinal Products (CPMP/BWP/410/01, rev. 43) should be considered.

4. Aspects to consider on the production and quality control of animal immunoglobulins and immunoserum for human use

4.1. *Characterisation of the Animal Immunoglobulin/Immunoserum during Development*

The active ingredient of any new immunoglobulin/immunoserum should be characterised by chemical and biological methods. Particular attention should be paid to use a wide range of analytical techniques for exploring different physico-chemical properties of the immunoglobulin. A clear difference should be made between the analytical tests performed during development in order to fully characterise the immunoglobulin, and tests performed routinely on each batch of the finished product.

It should be demonstrated that the product has a characteristic pattern of antigen-binding. Desired or undesired secondary processes known to be induced after the binding with the target antigen should be investigated. It should be shown that the product consists of a defined immunoglobulin G concentration. The content of other immunoglobulin classes should be investigated

The product should not contain antibodies that cross-react with human tissues to a degree that would impair clinical safety. In the event that erythrocytes were used for absorption, the level of content of haemoglobin should be demonstrated to be low. The protein content, the composition of protein, the degree of aggregation and molecular fragmentation of the immunoglobulin should be determined. When human blood cells have been used for absorption, the content of haemagglutinins and haemolysins should be demonstrated to be low.

The immunoreactivity of the immunoglobulin should be assessed. The specific activity of the purified immunoglobulin should be determined.

4.2. Points to Consider in Manufacture

Most of the techniques used to manufacture anti-venoms or anti-toxin immunosera are based on the data published on tetanus and diphtheria antitoxins, i.e. ammonium sulfate precipitation, peptic digestion, thermocoagulation and aluminium gel absorption. Other products like anti-lymphocyte immunoglobulins/immunosera are produced by combinations of chromatographic and precipitation steps. Because of the large variety of methods used for manufacturing, the quality of the products varies widely.

The main manufacturing steps consist of the preparation of the immunisation antigen, the immunisation of animals, collection of serum, absorption of undesired antibodies, purification including steps for removal or inactivation of viruses, formulation and filling. The absorption of unwanted antibodies may involve human tissue or cells.

Several of the requirements relating to establishments in which biological products are manufactured apply to the manufacture of animal immunoglobulins/immunosera (e.g. WHO, Technical Report Series 822, 1992: Annex 1 Good Manufacturing Practices for Biological Products; EU Guide for Good Manufacturing Practice for Medicinal Products and Annex I to the EU Guide to GMP: Manufacture of sterile medicinal products). Specific information can be found in WHO Technical Report Series, 413, 1969: Annex 2: Requirements for Immunosera of Animal Origin.

4.2.1. Animals used in the Manufacturing Process

The marketing authorisation holder of the immunoglobulin/immunosera has the responsibility for ensuring that the starting material comes from documented and recorded sources, and should perform regular audits of the farms supplying animals. The animals used should be a species approved by the competent authority, healthy and exclusively reserved for production of immunosera. The supplier of animals should be subject to routine legal supervision by the competent veterinary authority.

The donor animals should be held in a closed breeding and production colony, whenever possible. The strain, origin and number of the animals should be specified. Transport and introduction of the animals into production should follow specified procedures, including definition of quarantine measures. If different requirements apply to breeding and production animals this should be specified in the Marketing Authorisation Dossier. For large animals, the differentiation between breeding and production animals may not be applicable. Source, identity and control of animals taken to complete the herd should be recorded. The feed should originate from a controlled source and no animal proteins should be added.

If the animals are treated with antibiotics there should be a suitable withdrawal period before collection of blood or plasma. The animals must not be treated with Penicillin antibiotics. If a live vaccine is administered to the animals, a suitable waiting period is imposed between the vaccination and collection of plasma for Immunosera/immunoglobulin production.

A regular health monitoring system should be in place which ensures that the animals are subject to continuous and systematic veterinary and laboratory monitoring for freedom from specified infectious agents. This should include constant monitoring of the animal colonies by the veterinarian, routine pathological examination of randomly selected animals, serological analysis for a range of viruses, bacteria and parasites and the examination of the health status of all animals by the responsible veterinarian, or a person under the responsibility of this veterinarian, prior to bleeding.

The Annex to this guideline provides examples of viruses which the company should consider when establishing a system of health control of the animals used as plasma/serum donors for their specific product. The number of animals which should be tested for and the frequency of testing depend on various factors and should be specified for each product depending on the epidemiology of the agent, the size of the herds and the incidence of infections. Testing for viruses should be performed in laboratories with experience in routine virus testing.

The results of the health monitoring of the animal colonies should be well documented and newly emerging serious veterinary diseases should immediately be reported to the competent authorities.

4.2.2. Starting Materials

Biological materials used in the production

Any reagents of biological origin used in the production of the immunoglobulin/immunoserum should be monitored for microbial contaminants such as mycoplasma, fungi and bacteria. Special consideration should be given to possible viral contaminants and tests for relevant viruses should be performed. Bovine sera used as supplement, e.g. in culture media used for culture of the cell line providing the immunisation antigen should be checked and found negative for potential virus contaminants (at least bovine viral diarrhoea, infectious bovine rhino-tracheitis and para-influenza 3 virus). Preferentially, inactivated bovine serum should be used. In addition, bovine sera and other bovine-derived biologicals used as supplements during the manufacturing procedure should comply with the requirements in the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy via Human and Veterinary Medicinal Products

Antigens for immunisation

A number of different antigens are used, e.g.

- human antigens like thymocytes or permanent lymphocyte cell lines to produce anti-lymphocyte-cell sera
- venoms from snakes, scorpions and spiders to produce anti-venoms
- toxins to produce anti-toxins
- viral and bacterial antigens

The antigens should be appropriately characterised. Information on the source and method of preparation should be provided. If appropriate, identification and sanitary status, age of the animal from which the antigen originates should be known. If the antigen is derived from a human donor, information concerning the health of the donor should be provided. Antigens derived from human tissues should be shown to be free of infectious agents. When a cell line is used, this cell line should be characterised according to the relevant requirements, e.g. CPMP/ICH/294/95 Note for Guidance "Derivation and characterisation of cell substrates used for production of biotechnological/biological products" and should be shown to be free of adventitious agents according to the CPMP/ICH/295/95 Note for Guidance.

Material used for absorption of undesired antibodies

There are products whose manufacture includes steps for absorption of cross-reacting or unwanted anti-human antibodies. For this purpose, material from human tissues and/or blood is mainly used. The human materials should be shown to be free of infectious agents. The donors of the human material for absorption should comply with the requirements for donors of blood and plasma according to the Ph. Eur. monograph "Human plasma for fractionation". The origin, time of collection and testing should be specified. Any deviation from these requirements should be justified. It is preferred to subject these materials to viral inactivation.

4.2.3. Production Process

Immunisation of the animals

The animals are immunised with antigens according to a defined scheme with booster injections at regular intervals. The use of adjuvant agents is permitted. The serum collection and the immunoglobulin/immunoserum production should be performed in separate rooms. The animals from which the serum is collected may be anaesthetised. They should be thoroughly examined, particularly for evidence of infections. If an animal shows any pathological lesions, relevant to the use of the serum in the preparation, it should not be used, nor any remaining animals of the group concerned, unless it is evident that their use will not impair the safety of the product.

Blood or plasma collection

Collection of blood or plasma from animals should be made by venepuncture or intracardiac puncture. The area surrounding the point at which insertion is made into the vein should be cleaned and disinfected. The blood should be collected in such a manner as to maintain sterility of the product. If the blood/plasma is held for any period before further processing, it should be treated and stored in such a way as to exclude microbial contamination. Further storage before processing should be validated to ensure that the quality of the product is not influenced.

Pool-Testing

The freedom of contaminating viruses should be supported by testing either the serum pool or in the event that the manufacturing procedure contains a step of absorption, the first defined manufacturing step after absorption. The earliest step at which the serum obtained from all animals is assembled should be defined as the serum pool. The pool should be tested for the absence of specific and adventitious viruses using appropriate in vitro and, if appropriate, in vivo tests. The program to be established to test for absence of specific viruses depends on the individual manufacturing process. Thus, when human blood is used for absorption of unwanted antibodies and/or for immunisation the absence of human viruses, at least HCV, HIV 1 /2 and HBV, should be demonstrated.

In the event of viral contamination detection in the pooled serum, evidence should be presented that this viral contamination has been eliminated or inactivated during the manufacturing process.

Purification

The batch of a product intended for further processing should be clearly defined. Methods used to purify the product and their in-process controls including their specification limits should be described in detail, justified and validated. It is important to ensure that purification procedures do not impair relevant immunobiological features of the immunoglobulin/ immunoserum.

The flowcharts and descriptions of the manufacturing procedure should be detailed. Any optional variations of the manufacturing procedure should be validated. Criteria for reprocessing of any

intermediate or of the final bulk should be carefully defined, and the procedure of reprocessing should be validated and justified.

The parallel purification of several intermediate serum pools is possible. The maximum number of these intermediate pools and their volume should be defined.

All possible steps should be taken to prevent aggregation. The residues deriving from the purification procedure should be tested for. It is important that the techniques used to demonstrate purity be assessed using as wide a range of methods as possible, including physico-chemical and immunological techniques. These should include tests for protein contaminants of the host and - if relevant – of human origin, as well as tests on materials derived from the purification process. The level of contamination with host proteins considered as acceptable should be justified and criteria of acceptance or rejection of a production batch should be given. Assays for endotoxin levels should be carried out.

The effectiveness of the manufacturing process to inactivate or remove potential viral contaminants is important for product safety. Unless otherwise justified, effective step(s) which inactivates or eliminates potential viral contaminants should be incorporated. Examples are solvent-detergent treatment, pasteurisation or appropriate filtration methods. Any inactivation process should not compromise the biological activity of the product.

Procedures, which make use of chromatography, should be accompanied by appropriate measures to ensure that column substances or any additional potential contaminants arising from their use do not compromise the quality and safety of the final product. Data on the characterisation of column material or material used for the precipitation of the protein including data on the purification, cleaning, storage and repeated use of these materials should be provided.

The composition and source of any cell-culture media, buffers, other products and substances used for production should be recorded.

Residues remaining from the purification process should be tested for and relevant specifications should be defined. The stability of intermediates should be demonstrated.

Validation of the purification procedure

The capacity of the purification procedure to remove unwanted host derived proteins, additives used as part of the purification, viruses and other impurities should be investigated thoroughly. The reproducibility of the purification process with respect to its ability to remove specific contaminants should be demonstrated.

Specific studies should be performed to investigate the capacity of the purification process to inactivate or remove viruses. The principles of the Note for Guidance CPMP/268/95 "Virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses" have to be applied. If human materials are used for immunisation and absorption, human viruses should be considered in addition to species-specific viruses in selecting appropriate viruses for spiking studies. The validation of the purification process should also include justification of the working conditions such as column loading capacity, column regeneration and sanitisation and length of use of the columns as well as the use of any other substances such as precipitation substances.

Antimicrobial agents

Although antimicrobial agents are allowed to be added according to the Ph. Eur. monograph "Immunosera", they should not be included in the manufacture unless their use is justified by quality and/or safety considerations. They must never be used as a substitute for any aspect of GMP. In

particular, this should be taken into account for products to be administered intravenously and in large doses.

In selecting a preservative system the applicant should consider its effectiveness against potential microbial contaminants, possible interaction with the formulation or container and possible effects on testing in biological systems.

If replacement of preservatives is considered on the basis of side effects or for other reasons, a risk/benefit evaluation should be made, taking into consideration that such a change implies a new formulation with the need for additional studies for sterility, potency, stability and their clinical implications on a case by case basis.

5. The Final Bulk Product

The quality of all components of the final preparation forming the final bulk product should comply with the specifications of the relevant monographs of the Ph. Eur., when available. The amount of active substance should be adjusted according to the protein concentration or activity. The bulk product should be shown to be free from bacterial, fungal and other microbial contamination.

6. The Finished Product/Release Testing

Quality control tests should be carried out routinely on each batch of finished product according to the GMP guidelines. The aim of the release testing of a given batch is to show that this batch is consistent with and equivalent to the successive batches produced and to batches that have been shown to be safe and efficacious in clinical trials in man. The tests should be performed as laid down in the Marketing Authorisation. Among all tests included in the specifications for release testing, most have to be carried out on the product in its final container

Identity

A selection of tests used to characterise the immunoglobulin should be used to confirm product identity for each batch. The methods employed should include tests for biological activity as well as physicochemical and immunological methods. Using antisera specific to plasma proteins of each species of domestic animal commonly used in the preparation of materials of biological origin in the country concerned, it should be demonstrated that the product is shown to contain only proteins originating from the species used for the immunoglobulin production. The typical protein composition should be specified and tested for.

Purity

The degree of purity will depend on several factors; these include the method of its production and purification and the degree of consistency of the production process. The purity of each batch should be established and be within specified limits. The product should be shown to be free from microbial contamination. Pyrogenicity should be tested for. Particular attention should be given to assessing the degree of aggregation or molecular fragmentation of the immunoglobulin. The protein content of the product must be as low as possible relating to its specific activity. The content of characteristic protein impurities or stabilisers e. g. albumin should be specified.

Potency

The biological activity of the animal immunoglobulin/immunosera should be established by a biological assay. The test for potency should give information on the functional property of the immunoglobulin. Currently, most of the tests are based on protective or therapeutic effects of the

animal immunoglobulin/immunoserum determined in animals. For example, the dose necessary to protect 50% of a group of mice challenged with a specified, normally lethal, dose of venom or toxin may be determined. It is highly desirable to avoid the use of animals by substituting in vitro methods. Thus, the potential use of in vitro methods should be investigated. The characteristic antigen-binding pattern of the product needs to be demonstrated. However, correlation to the protective or therapeutic effect should be established. To verify the biological activity the use of cell based assays is highly encouraged. For example for animal anti-T lymphocyte immunoglobulin complement-dependent cytotoxicity on target cells is used.

Other parameters which should be tested for include sterility, pH and content of antimicrobial preservatives.

Stability

Stability studies should be performed to provide data to support the requested storage period for either drug substance (bulk material) or drug product (final container product). The data should be based on real-time and real-condition investigations. Depending on the product, it may be feasible to obtain data on the stability of the product during transport and storage at higher temperatures. If loss of activity during storage is revealed by stability studies, a shelf life specification should be established.

Specifications and reference material

The studies described in Section 4 will contribute to a definitive specification list for the product, when justified by the information obtained from the examination of successive batches and results of batch analyses as indicated in Section 6.

When an international reference preparation is not available, an in-house reference preparation should be produced. This should originate from a suitable batch of the product which has been clinically evaluated and fully characterised in terms of chemical composition, purity, potency and biological activity. Criteria for establishing the reference preparation and criteria for re-testing and prolongation of the shelf-life should be stated.

7. Consistency of the Manufacturing Process

Evidence should be provided on the consistency of production on at least three consecutive full-scale production batches. This should include information on the final bulk, finished product as well as on in-process controls. The studies should include biological, chemical and immunological methods to characterise the animal immunoglobulin/immunoserum as well as methods to detect and identify impurities.

Annex: Potential Viral Contaminants

Tables 1 to 3 give examples of viruses that a marketing authorisation applicant should consider when establishing a system of health control of the animals used as plasma donors. This system should be established individually for each product taking the following into account for the concerned species:

- the epidemiology of infectious disease in the country or geographical region where the production animals are maintained,
- the use of a strict barrier system which effectively protects the animals from contact with wild animals, including rodents,
- the provision of a reliable system of veterinary control,
- the testing of donor animals or randomly selected animals before entering the colony and at regular intervals thereafter.

The occurrence/absence of infectious diseases in the country of origin should be substantiated by an official certificate of a legal veterinary authority. In this certificate the legal authority should also confirm that a compulsory notification of suspected cases of infectious diseases including clinical and laboratory verification, is in place.

In general, the company should routinely monitor the epidemiological situation in the country of origin of its plasma and in particular take note of any new emerging veterinary diseases and amend its list of considered viruses accordingly, if necessary.

Table 1: Rabbit

Rabbit rotavirus

Reovirus type 3*

Poxviruses:

Rabbitpox (RPXV)*

Myxomatosis virus (MYXV)

Shope fibroma virus

Rabbit haemorrhagic disease virus (RHDV)

Rabbit papillomaviruses (e.g., Shope papillomavirus)

Lapine parvovirus (LPV)

Rabbit kidney vacuolating virus

Herpes cuniculi

Adenovirus

Encephalomyocarditis virus

Borna disease virus*

Sendai virus*

Simian Parainfluenza (SV-5)*

Pneumonia virus of mouse (PVM)

* Virus classified as pathogenic for humans

Table 2: Horse

Eastern, Western & Venezuelan Equine encephalitis viruses*

St Louis encephalitis virus (SLEV)*

Japanese B encephalitis virus*

Vesicular stomatitis virus (VSV)*

Equine herpesvirus, type 1-4*

West Nile fever virus (WNFV)*

Equine morbilli virus (Hendra)*

Borna disease virus*

Reovirus type 1-3*

Equine influenza virus*

Equine rotavirus

Equine and bovine papillomaviruses (EqPV 1-2 and BPV 1-2)

Equine infectious anaemia virus (EIAV)

Equine arteritis virus

African Horse Sickness(Orbi)

Equine parvovirus

* Virus classified as pathogenic for humans

Table 3: Seep & goat

Foot and mouth disease virus (FMDV)*

Wesselbron virus*

Louping ill virus (LIV)*

Rift valley fever complex*

Tick-borne encephalitis virus (TBEV)*

Bluetongue virus (BTV)*

Vesicular stomatitis virus (VSV)*

Poxviruses:

Parapoxvirus (Orf)*

Capripox virus*

Cowpox virus*

Parainfluenza virus type 3 (PIV-3)*

Borna disease virus*

Reovirus 1-3

Respiratory syncytial virus

Rotavirus

Akabane virus

Ovine herpes virus 2

Bovine herpes virus types 1,2,4

Border disease virus (BDV)

Ovine/bovine papillomavirus (OPV)

Bovine viral diarrhoea virus (BVDV)

Retroviruses:

Caprine arthritis encephalitis virus (CAEV)

Maedi-Visna virus (MVV)

Jaagsiekte virus (OPAV)

Bovine leukemia virus (BLV)

Epizootic haemorrhagic disease virus

Peste des petits ruminants (Morbillivirus)

Adenoviruses

Nairobi sheep disease

Ross river virus

* Virus classified as pathogenic for humans